Enyo Pharma: Clinical Trials

12 trials sponsored by Enyo Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 terminated, 1 recruiting. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Recruiting 1
Phase 25Completed 3, Terminated 2

Follow Enyo Pharma: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions
EYP651/Vonafexor low dose, EYP651/Vonafexor high dose, EYP651/CYP3A4 inhibitor - Healthy Adult Male and Female Volunteers
Phase 1RecruitingEnyo Pharma402025-10-282026-02-27
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Vonafexor low dose, Vonafexor high dose - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Phase 2TerminatedEnyo Pharma102025-07-012026-04-23
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Vonafexor - Alport Syndrome
Phase 2CompletedEnyo Pharma262024-08-012026-02-09
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
EYP001a, Entecavir, Pegylated interferon alpha2a - Hepatitis B, Chronic
Phase 2CompletedEnyo Pharma202020-05-252022-08-25
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic
Phase 2TerminatedEnyo Pharma262020-05-122022-11-02
Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose
[14C]-EYP001a - Healthy
Phase 1CompletedEnyo Pharma62019-07-242019-09-11
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
EYP001a - NASH - Nonalcoholic Steatohepatitis, Healthy
Phase 1CompletedEnyo Pharma162019-06-112020-09-25
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
Vonafexor, Placebo - Non-alcoholic Steatohepatitis
Phase 2CompletedEnyo Pharma1202019-01-302023-05-06
Drug Drug Interaction Study for EYP001 With Entecavir
EYP001, Entecavir 1 MG - Hepatitis B, Chronic
Phase 1CompletedEnyo Pharma162018-02-122018-07-26
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
EYP001a, Placebo, Entecavir - Hepatitis B, Chronic
Phase 1CompletedEnyo Pharma732017-09-212018-08-21
EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection
EYP001a - Hepatitis B, Chronic
Phase 1CompletedEnyo Pharma112017-02-102018-03-05
Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects
EYP001a, Placebo - Healthy
Phase 1CompletedEnyo Pharma802016-08-012017-04-13

Conditions studied

Hepatitis B, Chronic (5)  ·  Non-alcoholic Fatty Liver Disease (2)  ·  Liver Diseases (1)  ·  Nephritis, Hereditary (1)  ·  Renal Insufficiency, Chronic (1)

Interventions

entecavir (4)  ·  peginterferon alfa-2a (2)  ·  Cytochrome P-450 CYP2C8 (1)  ·  Cytochrome P-450 CYP3A Inhibitors (1)  ·  Tenofovir (1)

Countries

Australia (4)  ·  France (3)  ·  Netherlands (3)  ·  Hong Kong (2)  ·  Poland (2)  ·  South Korea (2)  ·  United States (2)  ·  Belgium (1)  ·  Germany (1)  ·  Puerto Rico (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Angela Molga, M.D. FRACP (1)  ·  C. Voors-Pette, MD (1)

Results publications

PMID 36334688, PMID 40938675

NIH funding

2016 (2), 2017 (1), 2018 (1), 2023 (1), 2025 (1)